The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.Accesswire • 01/10/25
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens BermanPRNewsWire • 01/09/25
Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action LawsuitGlobeNewsWire • 01/08/25
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action LawsuitGlobeNewsWire • 01/08/25
Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class ActionBusiness Wire • 01/08/25
REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their RightsGlobeNewsWire • 01/08/25
REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. InvestorsBusiness Wire • 01/08/25
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025GlobeNewsWire • 01/07/25
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall StreetThe Motley Fool • 01/02/25
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept ResultsGlobeNewsWire • 12/19/24
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease StudyZacks Investment Research • 12/18/24
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/17/24
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive YearGlobeNewsWire • 12/16/24
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & KorsinskyAccesswire • 12/10/24
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of LymphomaGlobeNewsWire • 12/09/24
Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.Accesswire • 12/09/24
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to RavulizumabGlobeNewsWire • 12/08/24
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire • 12/06/24
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of InvestorsPRNewsWire • 12/06/24
Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud AllegationsAccesswire • 12/06/24
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)Seeking Alpha • 12/05/24